xmab10171

XMAB10171 is a humanized antibody drug candidate engineered using Xencor's proprietary XmAb Fc technology platforms, designed for autoimmune disease indications[3][5][6]. It incorporates either an Xtend Fc Domain or a Cytotoxic Fc Domain, enhancing half-life and effector functions[3]. The precise mechanism, targets, and disease indications, as well as trial specifics, are not publicly disclosed in detail, but it is distinct from the oncology-focused bispecific XmAb20717 and is specifically part of Xencor's pipeline for autoimmune and inflammatory diseases[3][5][6]. Early clinical results mention initial evidence of anti-tumor activity, suggesting immune modulation, with tolerability and manageable cytokine release syndrome in Phase 1 dose-escalation cohorts[6].

Brand names

XMAB10171XMAB-10171XMAB 10171

Other names

xmab10171xmab-10171xmab 10171